Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Northwestern University

Status and phase: Completed; Phase 2

Conditions: Grade II Meningioma; Anaplastic (Malignant) Meningioma; Recurrent Meningioma; Grade III Meningioma; Supratentorial Meningioma; Atypical Meningioma

Treatments: Device: NovoTTF-200A Device; Procedure: Electric Field Therapy; Procedure: Quality-of-Life Assessment; Biological: Bevacizumab

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT02847559

NU 16C02 (Other Identifier)

STU00203030

P30CA060553 (U.S. NIH Grant/Contract)

NCI-2016-01026 (Registry Identifier)

Details and patient eligibility

About

The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune is also considered investigational because the US FDA has not approved its use for the treatment of meningiomas. Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient's brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed.

Full description

PRIMARY OBJECTIVES:

I. TTo determine the efficacy of Optune (TTF) therapy with Bevacizumab as assessed by Progression Free Survival (PFS) at 6 months (PFS-6) in patients with recurrent or progressive meningioma. PFS-6 will be defined from the time of registration to the time of confirmed progression. In cases where this might be unclear, patients may continue on trial and if progression is confirmed later, then the original date where first changes occurred will be used.

SECONDARY OBJECTIVES:

I. To collect the safety and tolerability data of Optune (TTF) therapy in combination with bevacizumab. II. To determine overall survival (OS). III. To determine tumor response rate (TRR). IV. To determine Objective Response Rate (ORR) V. To assess quality of life with treatment (QOL) using FACT-Br questionnaire.

OUTLINE:

This is a trial of Optune with concurrent standard of care treatment bevacizumab. Both treatments can start simultaneously with either starting first, but both must start within a window of 1 week. Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily for at least18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are responding will remain on study treatment for 6 months.After 6 months, patients may still continue on OPTUNE and Bevacizumab at the discretion of their treating physician. NOTE:At any point, if patients discontinue bevacizumab secondary to side effects, then they may continue Optune alone per treating physician's discretion.

After completion of study treatment, patients are followed up every 3 months for 2 years.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have a histologic diagnosis of meningioma, World Health Organization (WHO) grade 2 or 3 (atypical or anaplastic)
• Patients must have measurable disease recurrence. Recurrence must be documented by MRI scan.
• All patients must have developed recurrent disease/progression (evidence of recurrence to be established by MRI scan with contrast. There is no limit to the number of relapses) after receiving all standard treatments, which must include the following: surgical resection, if possible; definitive radiation therapy for unresectable meningioma, or for recurrent meningioma after resection. (Note: At registration, patients must be at least 28 days post-surgery, and must be at least 28 days post-radiation therapy, with resolution of related cytotoxicities down to Grade 2).
• Patients may have had any previous systemic treatment regimens (no limit to number of prior therapies). Patients with prior treatment with bevacizumab are eligible for enrollment into the study, Note: Except for bevacizumab, a 28 day wash-out period prior to registration is mandatory for all systemic treatments
• Patients must be age ≥ 18 years. Both males and females and patients from all ethnic backgrounds are eligible.
• Life expectancy of at least 12 weeks.
• Karnofsky performance status ≥ 60 % (see appendix 1).
• Patients must have adequate bone marrow, kidney, and liver function, (within 14 days prior to registration), defined as: Platelets ≥ 100,000/L, PT/INR/PTT ≤ 1.5x ULN (for patients on warfarin, INR should be maintained within therapeutic limits (either 2-3 or 2.5-3.5 for heart valve patients), AST and ALT ≤ 2.5 x institutional upper limit of normal (ULN), Total bilirubin ≤ 1.5 x institutional ULN, Serum creatinine ≤ 1.5 x institutional ULN
• Females of child-bearing potential (FOCBP) and males with partners of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study treatment; should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; likewise, if the female partner of a male patient becomes pregnant or suspect she is pregnant, he should inform his treating physician immediately

NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy

• Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)

  • FOCBP must have a negative serum or urine pregnancy test within 14 days prior to registration on study
  • Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
  • Patients must be able to comply with all protocol requirements

Exclusion criteria

• Patients who have had major surgery or significant traumatic injury within 4 weeks prior to registration, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study

• Patients who have had minor surgical procedures (with the exception of the placement of porta cath or other central venous access) within 7 days prior to registration

• Patients with spine only disease

• Patients may not be receiving any other investigational agents; (i.e. 28-day washout period from prior investigational drug is required)

• Patients may not receive any other anti-cancer therapies, within 28 days prior to registration and throughout the duration of this trial

• Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab are not eligible

• Patients with active implanted medical device, a skull defect (such as, missing bone with no replacement), a shunt or bullet fragments; examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts

• Patients with known sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes

• Patients with proteinuria within 14 days of registration as demonstrated by either: urine protein creatinine (UPC) ratio >= 1.0 at screening OR urine dipstick for proteinuria 2+ (patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection, and must demonstrate =< 1 g of protein/24 hours to be eligible)

• Patients with a serious non-healing wound, active ulcer, or untreated bone fracture

• Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)

• Patients with history of hematemesis or hemoptysis (defined as having bright red blood of 1/2 teaspoon or more per episode) within 28 days prior to registration

• History of myocardial infarction or unstable angina within 6 months of registration

• Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and /or diastolic blood pressure > 100 mmHg)

• History of stroke or transient ischemic attack within 6 months prior to registration

• Any prior history of hypertensive crisis or hypertensive encephalopathy

• History of abdominal fistula or gastrointestinal perforation within 6 months prior to registration

• Patients who have any severe and/or uncontrolled intercurrent medical conditions including, but not limited to any of the following, are not eligible:

  • Ongoing or active wound infection requiring concurrent systemic antibiotic treatment; there is no mandatory duration of time that a patient has to be off antibiotics, but the treating physician has to deem the infection as effectively treated prior to enrollment
  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Cardiac arrhythmia (New York Heart Association [NYHA] criteria)
  • Psychiatric illness/social situations that would limit compliance with study requirements, prevent patient comprehension of the nature of, and risk associated with, the study
  • Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints

• Female patients who are pregnant or nursing are not eligible

• Patients with evidence of increased intracranial pressure (midline shift >5mm, clinically significant papilledema, vomiting and nausea, or reduced level of consciousness).

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Treatment (bevacizumab, electric field therapy)

Experimental group

Description:

Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab 15 mg/kg IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment:

Biological: Bevacizumab

Procedure: Quality-of-Life Assessment

Procedure: Electric Field Therapy

Device: NovoTTF-200A Device